SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/30/19 Teladoc Health, Inc. 10-Q 9/30/19 84:8.4M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 1.24M 2: EX-10.1 Material Contract HTML 94K 3: EX-10.2 Material Contract HTML 40K 4: EX-10.3 Material Contract HTML 51K 5: EX-10.4 Material Contract HTML 51K 6: EX-10.5 Material Contract HTML 52K 7: EX-10.6 Material Contract HTML 52K 8: EX-10.7 Material Contract HTML 51K 9: EX-10.8 Material Contract HTML 50K 10: EX-10.9 Material Contract HTML 52K 11: EX-31.1 Certification -- §302 - SOA'02 HTML 31K 12: EX-31.2 Certification -- §302 - SOA'02 HTML 32K 13: EX-32.1 Certification -- §906 - SOA'02 HTML 26K 14: EX-32.2 Certification -- §906 - SOA'02 HTML 26K 61: R1 Document and Entity Information HTML 78K 25: R2 Consolidated Balance Sheets HTML 103K 48: R3 Consolidated Balance Sheets (Parenthetical) HTML 35K 72: R4 Consolidated Statements of Operations HTML 76K 62: R5 Consolidated Statements of Comprehensive Loss HTML 45K 26: R6 Consolidated Statements of Stockholders' Equity HTML 117K 49: R7 Consolidated Statements of Cash Flows HTML 118K 70: R8 Organization and Description of Business HTML 29K 64: R9 Basis of Presentation and Principles of HTML 43K Consolidation 65: R10 Revenue HTML 79K 76: R11 Business Acquisitions HTML 48K 45: R12 Intangible Assets, Net HTML 91K 20: R13 Goodwill HTML 39K 66: R14 Leases HTML 57K 77: R15 Accrued Expenses and Other Current Liabilities HTML 57K 46: R16 Fair Value Measurements HTML 70K 21: R17 Revolving Credit Facility HTML 26K 67: R18 Convertible Senior Notes HTML 126K 75: R19 Commitments and Contingencies HTML 31K 43: R20 Common Stock and Stockholders' Equity (Deficit) HTML 138K 36: R21 Income Taxes HTML 29K 58: R22 Basis of Presentation and Principles of HTML 45K Consolidations (Policies) 82: R23 Revenue (Tables) HTML 68K 44: R24 Business Acquisitions (Tables) HTML 44K 37: R25 Intangible Assets, Net (Tables) HTML 91K 59: R26 Goodwill (Tables) HTML 39K 83: R27 Leases (Tables) HTML 58K 42: R28 Accrued Expenses and Other Current Liabilities HTML 57K (Tables) 38: R29 Fair Value Measurements (Tables) HTML 68K 27: R30 Convertible Senior Notes (Tables) HTML 105K 50: R31 Common Stock and Stockholders' Equity (Deficit) HTML 131K (Tables) 73: R32 Organization and Description of Business (Details) HTML 50K 63: R33 Basis of Presentation and Principles of HTML 55K Consolidation - VIE (Details) 24: R34 Basis of Presentation and Principles of HTML 34K Consolidation - Segment and Foreign Operations (Details) 47: R35 Basis of Presentation and Principles of HTML 35K Consolidation - Accounting Pronouncements (Details) 71: R36 Revenue - Other Disclosures (Details) HTML 35K 60: R37 Revenue - Disaggregation and Other (Details) HTML 48K 23: R38 Business Acquisitions (Details) HTML 84K 51: R39 Intangible Assets, Net - Summary (Details) HTML 78K 33: R40 Goodwill (Details) HTML 31K 40: R41 Leases - Other (Details) HTML 33K 81: R42 Leases - Operating lease expense (Details) HTML 30K 57: R43 Leases - Supplemental information (Details) HTML 33K 32: R44 Leases - Future minimum lease payments (Details) HTML 39K 39: R45 Accrued Expenses and Other Current Liabilities HTML 61K (Details) 80: R46 Fair Value Measurements - Recurring (Details) HTML 55K 56: R47 Fair Value Measurements - Level 3 (Details) HTML 32K 31: R48 Revolving Credit Facility (Details) HTML 33K 41: R49 Convertible Senior Notes - Due 2025 - Terms HTML 69K (Details) 53: R50 Convertible Senior Notes - Due 2025 - Summary HTML 54K (Details) 28: R51 Convertible Senior Notes - Due 2022 - Terms HTML 69K (Details) 68: R52 Convertible Senior Notes - Due 2022 - Summary HTML 55K (Details) 78: R53 Common Stock and Stockholders' Equity - HTML 26K Capitalization (Details) 54: R54 Common Stock and Stockholders' Equity - Stock Plan HTML 97K and Stock Options (Details) 29: R55 Common Stock and Stockholders' Equity - Vesting HTML 30K (Details) 69: R56 Common Stock and Stockholders' Equity - Fair Value HTML 54K Assumptions (Details) 79: R57 Common Stock and Stockholders' Equity - Restricted HTML 83K Stock Units (Details) 52: R58 Common Stock and Stockholders' Equity - Employee HTML 48K Stock Purchase Plan (Details) 30: R59 Common Stock and Stockholders' Equity - HTML 37K Compensation Costs (Details) 55: R60 Income Taxes (Details) HTML 30K 84: XML IDEA XML File -- Filing Summary XML 137K 35: XML XBRL Instance -- tdoc-20190930x10qcd3842_htm XML 1.99M 22: EXCEL IDEA Workbook of Financial Reports XLSX 79K 16: EX-101.CAL XBRL Calculations -- tdoc-20190930_cal XML 157K 17: EX-101.DEF XBRL Definitions -- tdoc-20190930_def XML 537K 18: EX-101.LAB XBRL Labels -- tdoc-20190930_lab XML 1.26M 19: EX-101.PRE XBRL Presentations -- tdoc-20190930_pre XML 904K 15: EX-101.SCH XBRL Schema -- tdoc-20190930 XSD 154K 74: JSON XBRL Instance as JSON Data -- MetaLinks 310± 492K 34: ZIP XBRL Zipped Folder -- 0001558370-19-009443-xbrl Zip 295K
tdoc_Ex_10_5 |
Exhibit 10.5
AMENDMENT NO. 1 TO EXECUTIVE SEVERANCE AGREEMENT
This Amendment No. 1 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Ms. Mala Murthy, an individual resident in the State of New York (“Executive”), is made as of October 29, 2019.
Recitals
A. Teladoc and Executive are parties to that certain Executive Severance Agreement, dated as of June 24, 2019 (the “Agreement”).
B. Teladoc and Executive desire to make certain changes to the Agreement, as set forth in this Amendment.
Terms and Conditions
In consideration of the mutual covenants contained herein, along with other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:
1. Amendments.
1.1. Except as otherwise set forth in this Amendment, capitalized terms have the meaning given them in the Agreement.
1.2. A Section 8(k) is hereby added to the Agreement, as follows:
“(k) Governance Policies. During and, to the extent required by applicable law, regulation or exchange listing requirement, following the period of Executive’s employment with the Company, Executive shall be subject to all of the Company’s corporate governance and executive compensation policies in effect from time to time, including any stock ownership guidelines and the Company’s executive compensation recovery policy.”
1.3. Section 1(d) of the Agreement is hereby deleted in its entirety and replaced with the following:
“(d) “Cause” shall mean: (A) the willful and continued failure by Executive to substantially perform his or her duties to the Company (other than any such failure resulting from Executive’s incapacity due to physical or mental illness), after demand for substantial performance is delivered by the Company that specifically identifies the manner in which the Company believes Executive has not substantially performed his or her duties, which is not cured within thirty (30) days after notice of such failure has been given to the Executive by the Company; (B) the willful engaging by the Executive in misconduct that is significantly injurious to the Company, monetarily, in reputation or otherwise, including any conduct that is in violation of the written employee workplace policies of the Company; or (C) the Executive’s commission of any felony, or any crime involving dishonesty in respect of the business or affairs of the Company or any of its subsidiaries. No act, or failure to act, on the Executive’s part shall be
Page 1 of 6
considered “willful” unless done, or omitted to be done by him or her not in good faith and without reasonable belief that his or her action or omission was in the best interest of the Company.”
1.4. Section 1(h) of the Agreement is hereby deleted in its entirety and replaced with the following:
“(h) “Good Reason” shall mean one or more of the following, without Executive’s consent: (A) there is a material reduction in aggregate amount of Executive’s base salary and target bonus without Executive’s consent (except where there is a general reduction applicable to the management team generally); (B) there is a material reduction in Executive’s overall responsibilities or authority, or scope of duties below the position of a Chief Financial Officer of the Company; (C) Executive is required by the Company to relocate his or her principal place of employment outside of the New York City metropolitan area; or (D) the failure of the Company to obtain an agreement from any successor to all or substantially all of the business or assets of the Company to assume this Agreement as contemplated in Section 8(a) of this Agreement; or (E) any material breach by the Company of this Agreement. Furthermore, any provision of this Agreement to the contrary notwithstanding, “Good Reason” shall be deemed to exist if, in connection with or following a Change of Control, the Company’s common stock ceases to be publicly traded on a national securities exchange, unless Executive becomes (or continues as) the Chief Financial Officer (with the powers and responsibilities customarily associated with such title) of the ultimate parent entity, or successor to, the Company in such Change of Control, and the common stock of such parent entity or successor, as applicable, is publicly traded on a national securities exchange. It is understood that Executive must assert any termination for Good Reason by written notice to the Company no later than ninety (90) days following the date on which arises the event or events giving the Executive the right to assert such a termination, and the Company must have an opportunity within thirty (30) days following delivery of such notice to cure the Good Reason condition. In no instance will a resignation by Executive be deemed to be for Good Reason if it is made more than twelve (12) months following the initial occurrence of any of the events that otherwise would constitute Good Reason hereunder.”
1.5. Section 2(a) of the Agreement is hereby deleted in its entirety and replaced with the following:
“(a) Severance Upon Qualifying Termination. If Executive has a Qualifying Termination that does not occur prior to but in connection with, on the date of, or within twelve (12) months following a Change of Control, then subject to (x) the requirements of this Section 2(a), (y) Executive’s continued compliance with the terms of the Confidentiality Agreement and Sections 4 and 5 hereof and (z) the terms of Section 8 hereof, Executive shall be entitled to receive the following payments and benefits:
(i) The Company shall pay to Executive (A) his or her fully earned but unpaid base salary through the date of Executive’s Qualifying Termination, (B) any accrued but unpaid paid time off and (C) any other amounts or benefits, if any, under the Company’s employee benefit plans, programs or arrangements to which Executive is entitled pursuant to the terms of such plans, programs or arrangements or applicable law, payable in accordance with the terms of
Page 2 of 6
such plans, programs or arrangements or as otherwise required by applicable law (collectively, the “Accrued Rights”);
(ii) Executive shall receive continued payment of the Base Salary for a period of twelve (12) months following the termination date in accordance with the Company’s ordinary payroll practices;
(iii) The Company will pay Executive the amount of any earned but unpaid annual bonus for the calendar year immediately prior to the year in which Executive’s Qualifying Termination occurs, as determined by the Board (or an authorized committee) in its good faith discretion, payable in a lump sum at the same time annual bonuses are paid to other Company executives generally but in no event later than December 31 of the year in which Executive’s Qualifying Termination occurs;
(iv) If Executive timely elects continued coverage under COBRA for Executive and Executive’s covered dependents under the Company’s group health (medical, dental or vision) plans following such Qualifying Termination, then the Company shall pay the COBRA premiums necessary to continue Executive’s and his covered dependents’ health insurance coverage in effect on the termination date until the earliest of (x) twelve (12) months following the effective date of such Qualifying Termination, (y) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment (and Executive agrees to promptly notify the Company of such eligibility) and (z) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the Qualifying Termination date through the earlier of (x)-(z), in such case, the “COBRA Payment Period”). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on Executive’s behalf would result in a violation of applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act) or an excise tax, then in lieu of paying COBRA premiums pursuant to this Section 2(a)(iv), the Company shall pay Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding, such payment to be made without regard to Executive’s payment of COBRA premiums; and
(v) All unvested equity or equity-based awards granted to Executive under any and all equity compensation plans of the Company that were scheduled to vest within six (6) months after the date of Executive’s termination or resignation shall become immediately vested as to time, with any such awards that are subject to performance-based vesting conditions remaining eligible to vest to the extent the performance conditions are satisfied during such six-month period (provided that nothing in this Section 2(a) shall operate to extend the term, if any, of an award beyond the final expiration date provided in the applicable award agreement).”
1.6. Section 2(b) of the Agreement is hereby deleted in its entirety and replaced with the following:
“(b) Severance Upon Qualifying Termination Occurring in Connection with a Change of Control. If Executive has a Qualifying Termination that occurs prior to but in
Page 3 of 6
connection with, on the date of, or within twelve (12) months following a Change of Control, then subject to (x) the requirements of this Section 2(b), (y) Executive’s continued compliance with the terms of the Confidentiality Agreement and Sections 4 and 5 hereof and (z) the terms of Section 8 hereof, in lieu of the payments and benefits described in Section 2(a) above, Executive shall be entitled to receive the following payments and benefits:
(i) the Company shall pay to Executive the Accrued Rights; and
(ii) Executive shall receive continued payment of the Base Salary for a period of twelve (12) months following the termination date in accordance with the Company’s ordinary payroll practices; and
(iii) The Company shall pay Executive the amount of any earned but unpaid annual bonus for the calendar year immediately prior to the year in which Executive’s Qualifying Termination occurs, as determined by the Board (or an authorized committee) in its good faith discretion, payable in a lump sum at the same time annual bonuses are paid to other Company executives generally but in no event later than December 31 of the year in which Executive’s Qualifying Termination occurs; and
(iv) The Company shall pay Executive an additional amount equal to a pro rata portion of the annual bonus Executive would have earned for the year of termination, which bonus shall be determined based on Company financial performance results for such year, payable in a lump sum at the same time bonuses are paid to Company senior executives generally (but in no event later than March 15 of the year following the year in which Executive’s Qualifying Termination occurs); and
(v) The Company shall pay Executive an additional amount equal to one hundred percent (100%) of Executive’s annual target bonus, payable in a lump sum on the Company’s first ordinary payroll date occurring after the effective date of the later of Executive’s Qualifying Termination or the Change of Control; and
(vi) If Executive timely elects continued coverage under COBRA for Executive and Executive’s covered dependents under the Company’s group health (medical, dental or vision) plans following such Qualifying Termination, then the Company shall pay the COBRA premiums necessary to continue Executive’s and his covered dependents’ health insurance coverage in effect on the termination date until the earliest of (x) twelve (12) months following the effective date of such Qualifying Termination, (y) the date when Executive becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment (and Executive agrees to promptly notify the Company of such eligibility) and (z) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the Qualifying Termination date through the earlier of (x)-(z), in such case, the “COBRA Payment Period”). Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on Executive’s behalf would result in a violation of applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act) or an excise tax, then in lieu of paying COBRA premiums pursuant to this Section 2(b)(iv), the Company shall pay Executive on the last day of each remaining month of
Page 4 of 6
the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premium for such month, subject to applicable tax withholding, such payment to be made without regard to Executive’s payment of COBRA premiums; and
(vii) all unvested equity or equity-based awards granted to Executive under any and all equity compensation plans of the Company shall become immediately vested as to time and any such awards that are subject to performance-based vesting will remain eligible to vest to the extent the performance conditions are thereafter satisfied (provided that nothing herein shall operate to extend the term, if any, of an award beyond the final expiration date provided in the applicable award agreement).”
2. Other Provisions. Except as expressly set forth above, each and every provision of the Agreement shall remain unchanged and in full force and effect.
3. General Provisions. The provisions of Section 8 of the Agreement shall govern this Amendment, to the fullest extent applicable and are hereby incorporated into this Amendment.
[Signature page follows.]
Page 5 of 6
IN WITNESS WHEREOF, the parties have executed and delivered this Amendment as of the date first written above.
|
|
|
|
|
MS. MALA MURTHY, |
|
TELADOC HEALTH, INC., |
||
an individual resident in the |
|
|
a Delaware corporation |
|
State of New York |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
/s/ MALA MURTHY |
|
By: |
/s/ MICHELLE BUCARIA |
|
|
|
|
Name: |
Ms. Michelle Bucaria |
|
|
|
Title: |
Chief Human Resources Officer |
Page 6 of 6
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 10/30/19 | 8-K | ||
10/29/19 | ||||
For Period end: | 9/30/19 | |||
6/24/19 | 8-K | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/23/24 Teladoc Health, Inc. 10-K 12/31/23 120:12M 3/01/23 Teladoc Health, Inc. 10-K 12/31/22 121:15M Toppan Merrill Bridge/FA 2/28/22 Teladoc Health, Inc. 10-K 12/31/21 111:14M Toppan Merrill Bridge/FA 3/01/21 Teladoc Health, Inc. 10-K 12/31/20 126:15M Toppan Merrill Bridge/FA |